Saccharomyces boulardiiSaccharomyces boulardii contains 5 billion live microorganisms of pure Saccharomyces boulardii per capsule. S. boulardii is one of the only known probiotic yeasts in the world, and it was first discovered by French scientist, Henri Boulard in 1923. Saccharomyces boulardii is one of the most researched probiotics in the world and has been noted for its efficacy in diarrhoeal diseases, as well as its inhibition of certain pathogens.


Clinical Research on Saccharomyces boulardii and diarrhoea

McFarland, L.V. & Bernasconi, P. (1993) Saccharomyces boulardii: A Review of an Innovative Biotherapeutic Agent. Microbial Ecology in Health and Disease; Vol. 6 pp. 157-171.

Hochter, W. et al (1990) Saccharomyces boulardii in acute adult diarrhea. Efficacy and tolerance of treatment. Munchener Medizinische Wochenschrift; Vol. 132 (12) pp. 188-192.

Cetina-Sauri, G. & Basto, S. (1994) Therapeutic evaluation of Saccharomyces boulardii in children with acute diarrhea. Annales de Pediatrie; Vol. 41 (6) pp. 397-400.

Kurugol, Z. & Koturoglu, G. (2005) Effects of Saccharomyces boulardii in children with acute diarrhea. Acta Paediatrica; Vol. 94 pp. 44-47.

Maupas, J.L. et al. (1983) Treatment of Irritable Bowel Syndrome (IBS) Double Blind Trial of Saccharomyces boulardii. Medecine Chirurgie Digestives. Vol. 12 (1) pp. 77 – 79.

Kotowska, M. et al. (2005)Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Alimentary Pharmacology & Therapeutics 21 (5), 583–590

Erdeve, O. et al. (2004) 'The probiotic effect of S.boulardii in a pediatric age group' Journal of Trop Pediatr. Aug;50(4) pp.234-6

D'Souza, A. et al. (2002) Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. Care of the Elderly Section, Faculty of Medicine, Imperial College School of Medicine, Hammersmith Hospital, London. BMJ 2002;324:1361 ( 8 June )

Kirchhelle, A. et al. (1996) Treatment of persistent diarrhoea with Saccharomyces boulardii in returning travellers. Results of a prospective study; Fortschr Med; Vol. 114 (11) pp. 136-140

Grandy, G. et al. (2010) Probiotics in the treatment of acute rotavirus diarrhoea. A randomized, double-blind, controlled trial using two different probiotic preparations in Bolivian children; BMC Infectious Diseases, Vol. 10 pp. 253

Clinical Research on Saccharomyces boulardii and Candida

Ducluzeau, R. & Bensaada, M. (1982) Comparative effect of a single or continuous administration of Saccharomyces boulardii on the establishment of various strains of Candida in the digestive tract of gnotobiotic mice. Annales de microbiologie. (Inst. Pasteur). 133: pp: 491-501

Jawhara, S. & Poulain, D. (2007) Saccharomyces boulardii decreases inflammation and intestinal colonisation by Candida albicans in a mouse model of chemically-induced colitis. Medical Mycology, Vol. 45. Issue 8. pp 691 - 700.

Berg, R. et al. (1993) Inhibition of Candida albicans translocation from the gastrointestinal tract of mice by oral administration of Saccharomcyes boulardii. J Infect Dis. 1993,Nov;168(5):1314-8.

Murzyn, et al. (2010) Capric Acid Secreted by S. boulardii Inhibits C. Albicans. August 2010, Plos One, Vol. 5. Issue 8.

Clinical Research on Saccharomyces boulardii and Clostridium difficile disease

McFarland, L.V. et al. (1994) A randomised placebo-controlled trial of saccharomyces boulardii in combination with standard antibiotics for clostridium difficile disease. The Journal of the American Medical Association. Vol. 271. pp. 1913 - 1918

Surawicz, C.M. et al (2000) The Search for a Better Treatment for Recurrent Clostridium difficile Disease: Use of High-Dose Vancomycin Combined with Saccharomyces boulardii. Clinical Infectious Diseases. Vol. 31 pp. 1012 – 1017

Buts, J. et al. (1993) Saccharomyces boulardii for Clostridium difficile-Associated Enteropathies in Infants. Journal of Pediatric Gastroenterology and Nutrition. Vol. 16 pp. 419 – 425

Surawicz, C.M. et al. (1989) Treatment of Recurrent Clostridium difficile Colitis with Vancomycin and Saccharomyces boulardii. The American Journal of Gastroenterology. Vol. 85 (10)

Surawicz, C.M. (2003) Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans. Best Practice & Research Clinical Gastroenterology. Vol. 17 (5) pp. 775 – 783

Castagliuolo, I. et al. (1999) Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun. 67(I): 302 - 307.

Pothoulakis, C. et al. (1993) Saccharomyces boulardii inhibits Clostridium difficile toxin: A binding and enterotoxicity in rat ileum. Gastroenterology: 104(4): 1108 - 1115.

Tung, J.M et al. (2010) Prevention of Clostridium difficile with Saccharomyces boulardii: A systematic review; Canadian Journal of Gastroenterology, Vol. 23(12) pp. 817-821

Clinical Research on Saccharomyces boulardii and Inflammatory Bowel Disease

Guslandi, M. et al. (2000) Saccharomyces boulardii in Maintenance Treatment of Crohn's Disease. Digestive Diseases & Sciences. Vol 45, 7, 1462 - 1464.

Guslandi, M. et al. (2003) A pilot trial of Saccharomyces boulardii in ulcerative colitis. European Journal of Gastroenterology & Hepatology. Vol. 15 pp. 697 – 698.

disclaimer